Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma

Journal of Hepatology

Volumn 46, Issue 1, 2007, Pages 45-52

  Lin, Shi Ming ^a   Yu, Ming Lung ^b   Lee, Chuan Mo ^c   Chien, Rong Nan ^a   Sheen, I Shyan ^a   Chu, Chia Ming ^a   Liaw, Yun Fan ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Chronic hepatitis B; Cirrhosis; HBeAg seroconversion; Hepatocellular carcinoma; Interferon

Indexed keywords

ALPHA INTERFERON; CORTICOSTEROID; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; RECOMBINANT ALPHA2A INTERFERON;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VIRUS INFECTION;

ADULT; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE;

EID: 33751514752     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.08.021     Document Type: Article

References (36)

1. Chu C.M., and Liaw Y.F. Natural history differences in perinatally versus adult-acquired disease. Curr Hepat Rep 3 (2004) 123-131
2. Wong D.K.H., Cheung A.M., O'Rourke K., Naylor C.D., Detsky A.S., and Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 119 (1993) 312-323
3. Cohard M., Poynard T., Mathurin P., and Zarski J.P. Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect meta-analysis. Hepatology 20 (1994) 1390-1398
4. Niederau C., Heintges T., Lange S., Goldmann G., Niederau C.M., Mohr L., and Haussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334 (1996) 1422-1427
5. Ikeda K., Saitoh S., Suzuki Y., Kobayashi M., Tsubota A., Fukuda M., Koida I., et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus. A pilot study. Cancer 82 (1998) 827-835
6. Lin S.M., Sheen I.S., Chien R.N., Chu C.M., and Liaw Y.F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29 (1999) 971-975
7. Lau D.T.Y., Everhart J., Kleiner D.E., Park Y., Vergalla J., Schmid P., et al. Long-term follow up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 113 (1997) 1660-1667
8. Korenman J., Baker B., Waggoner J., Everhart J.E., Di Bisceglie A.M., and Hoofnagle J.H. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 114 (1991) 629-634
9. Lin S.M., Tai D.I., Chien R.N., Sheen I.S., Chu C.M., and Liaw Y.F. Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B. J Viral Hepat 11 (2004) 349-357
10. Yuen M.F., Hui C.K., Cheng C.C., Wu C.H., Lai Y.P., and Lai C.L. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 34 (2001) 139-145
11. van Zonneveld M., Honkoop P., Hansen B.E., Niesters H.G.M., Murad S.D., de Man R.A., et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 39 (2004) 804-810
12. Kao J.H. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 17 (2002) 643-650
13. Liaw Y.F., Tai D.Y., Chu C.M., Lin D.Y., Sheen I.S., Chen T.J., and Pao C.C. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 90 (1986) 263-267
14. Liaw Y.F. Acute exacerbation and superinfection in patients with chronic viral hepatitis. J Formosan Med Assoc 94 (1995) 521-528
15. Liaw Y.F., Pao C.C., Chu C.M., Sheen I.S., and Huang M.J. Changes of serum hepatitis B virus DNA in two types of clinical events preceding spontaneous hepatitis B e antigen seroconversion in chronic type B hepatitis. Hepatology 7 (1987) 1-3
16. Chien R.N., Yeh C.T., Tsai S.L., Chu C.M., and Liaw Y.F. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 38 (2003) 1267-1273
17. Liaw Y.F., Tai D.I., Chu C.M., and Chen T.J. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 8 (1988) 493-496
18. Cox D.R. Regression model and life tables. J R Stat Soc B 34 (1972) 187-220
19. Liaw Y.F., Leung N., Guan G., Lau G.K.K., Merican I., McCaughan G., Gane E., et al. Asian Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 25 (2005) 472-489
20. Janssen H.L.A., Gerken G., Carreno V., Marcellin P., Naoumov N.V., Craxi A., et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. Hepatology 30 (1999) 238-243
21. Carreno V., Marcellin P., Hadziyannis S., Salmeron J., Diago M., Kitis G.E., et al. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 30 (1999) 277-282
22. Cooksley W.G.E., Piratvisuth T., Lee S.D., Mahachai V., Chao Y.C., Tanwandee T., et al. Peginterferon α-2a (40KD): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 10 (2003) 298-305
23. Lau G.K.K., Piratvisuth T., Luo K.X., Marcellin P., Thongsawat S., Coosley G., et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. New Engl J Med 352 (2005) 2682-2695
24. Yoshida H., Shiratori Y., Moriyama M., Arakawa Y., Ide T., Sata M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. HIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131 (1999) 174-181
25. Shiratori Y., Ito Y., Yokosuka O., Imazeki F., Nakata R., Tanaka N., et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 142 (2005) 105-114
26. Papatheodoridis G.V., Manesis E., and Hadziyannis S.J. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 34 (2001) 306-313
27. Lampertico P., Del Ninno E., Vigano M., Romeo R., Donato M.F., Sablon E., et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 37 (2003) 756-763
28. Yang H.I., Lu S.N., Liaw Y.F., You S.L., Sun C.A., Wang L.Y., et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Eng J Med 347 (2002) 168-174
29. Kao J.H., Wu N.H., Chen P.J., Lai M.Y., and Chen D.S. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 33 (2000) 998-1002
30. Wai C.T., Chu C.J., Hussain M., and Lok A.S. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 36 (2002) 1425-1430
31. Kao J.H., Chen P.J., Lai M.Y., and Chen D.S. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118 (2000) 554-559
32. Chan H.L., Hui A.Y., Wong M.L., Tse A.M.L., Hung L.C.T., Wong V.W.S., et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 53 (2004) 1494-1498
33. Yu M.W., Yeh S.H., Chen P.J., Liaw Y.F., Lin C.L., Liu C.J., et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 97 (2005) 265-272
34. Liaw Y.F., Sung J.J.Y., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
35. EASL Jury. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol. 2003;38:533-540.
36. Kanwal F., Gralnek I.M., Martin P., Dulai G.S., Farid M., and Spiegel B.M.R. Treatment alternatives for chronic hepatitis B virus infection: a cost-effective analysis. Ann Intern Med 142 (2005) 821-831